Square Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Square Pharmaceuticals has a total shareholder equity of BDT117.1B and total debt of BDT1.6B, which brings its debt-to-equity ratio to 1.4%. Its total assets and total liabilities are BDT135.9B and BDT18.9B respectively. Square Pharmaceuticals's EBIT is BDT17.4B making its interest coverage ratio -4.4. It has cash and short-term investments of BDT57.7B.
Key information
1.4%
Debt to equity ratio
৳1.62b
Debt
Interest coverage ratio | -4.4x |
Cash | ৳57.66b |
Equity | ৳117.07b |
Total liabilities | ৳18.86b |
Total assets | ৳135.93b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: SQURPHARMA's short term assets (BDT78.2B) exceed its short term liabilities (BDT16.7B).
Long Term Liabilities: SQURPHARMA's short term assets (BDT78.2B) exceed its long term liabilities (BDT2.2B).
Debt to Equity History and Analysis
Debt Level: SQURPHARMA has more cash than its total debt.
Reducing Debt: SQURPHARMA's debt to equity ratio has increased from 0% to 1.4% over the past 5 years.
Debt Coverage: SQURPHARMA's debt is well covered by operating cash flow (861.1%).
Interest Coverage: SQURPHARMA earns more interest than it pays, so coverage of interest payments is not a concern.